Survodutide and retatrutide are both investigational incretin peptides given as once-weekly subcutaneous injections, and neither is FDA-approved. The clearest mechanistic difference is receptor count: survodutide is a GLP-1/glucagon dual agonist, while retatrutide adds a third target (GIP) to make it a triple agonist. Because their trials differ in design, dose, and population, cross-trial efficacy comparisons are not reliable.
Reviewed for accuracy · Last reviewed July 8, 2026The honest mechanistic distinction is the receptor count. Survodutide activates GLP-1 and glucagon, while retatrutide adds GIP on top of that pair to act as a triple agonist. Whether adding GIP translates into a meaningful real-world difference is not something the current evidence lets anyone state as fact.
Both remain investigational, so neither has an approved label or a long-term human safety record. Their trial programs also differ: survodutide has been studied in obesity and separately in MASH with fibrosis, whereas retatrutide's published human data centers on a Phase 2 obesity trial. Because doses, endpoints, and populations differ, comparing reported weight-loss numbers across their trials would not be a fair head-to-head.
In their respective trials, both reported predominantly gastrointestinal side effects (nausea, vomiting, diarrhea) that were generally dose-related and concentrated during escalation. None of this is a substitute for medical advice, and independently sourced vials of either carry no guarantee of the testing a regulated product would receive.
This page is an independent educational reference and is not medical advice, and does not indicate any approval status for any use. Survodutide is investigational. Talk to a doctor before starting any compound.